Literature DB >> 24697150

Biomimetic urothelial tissue models for the in vitro evaluation of barrier physiology and bladder drug efficacy.

Simon C Baker1, Saqib Shabir, Jennifer Southgate.   

Abstract

The bladder is an important tissue in which to evaluate xenobiotic drug interactions and toxicities due to the concentration of parent drug and hepatic/enteric-derived metabolites in the urine as a result of renal excretion. Breaching of the barrier provided by the bladder epithelial lining (the urothelium) can expose the underlying tissues to urine and cause harmful effects (e.g., cystitis or cancer). Human urothelium is most commonly represented in vitro as immortalized or established cancer-derived cell lines, but the compromised ability of such cells to undergo differentiation and barrier formation means that nonimmortalized, normal human urothelial (NHU) cells provide a more relevant cell culture system. The impressive capacity for urothelial self-renewal in vivo can be harnessed in vitro to generate experimentally-useful quantities of NHU cells, which can subsequently be differentiated to form a functional or "biomimetic" urothelium. When seeded onto permeable membranes, these barrier-forming human urothelial tissue models enable the modeling of serum and luminal (intravesical) exposure to drugs and metabolites, thus supporting efficacy/toxicity assessments. Biomimetic human urothelial constructs provide a potential step along the preclinical trail and may support the extrapolation from rodent in vivo data to determine human relevance. Early evidence is beginning to demonstrate that human urothelium in vitro can provide information that supersedes conventional rodent studies, but further validation is needed to support widespread adoption.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24697150     DOI: 10.1021/mp500065m

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  8 in total

1.  Bladder organoids: a step towards personalised cancer therapy?

Authors:  Sreemoti Banerjee; Jennifer Southgate
Journal:  Transl Androl Urol       Date:  2019-07

Review 2.  Modeling human bladder cancer.

Authors:  Cassandra Ringuette-Goulet; Stéphane Bolduc; Frédéric Pouliot
Journal:  World J Urol       Date:  2018-06-14       Impact factor: 4.226

Review 3.  The urothelium: a multi-faceted barrier against a harsh environment.

Authors:  Nazila V Jafari; Jennifer L Rohn
Journal:  Mucosal Immunol       Date:  2022-09-30       Impact factor: 8.701

4.  A urine-dependent human urothelial organoid offers a potential alternative to rodent models of infection.

Authors:  Harry Horsley; Dhanuson Dharmasena; James Malone-Lee; Jennifer L Rohn
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

5.  Differentiation-associated urothelial cytochrome P450 oxidoreductase predicates the xenobiotic-metabolizing activity of "luminal" muscle-invasive bladder cancers.

Authors:  Simon C Baker; Volker M Arlt; Radek Indra; Madeleine Joel; Marie Stiborová; Ian Eardley; Niaz Ahmad; Wolfgang Otto; Maximilian Burger; Peter Rubenwolf; David H Phillips; Jennifer Southgate
Journal:  Mol Carcinog       Date:  2018-02-01       Impact factor: 4.784

6.  Characterization and classification of adherent cells in monolayer culture using automated tracking and evolutionary algorithms.

Authors:  Zhen Zhang; Matthew Bedder; Stephen L Smith; Dawn Walker; Saqib Shabir; Jennifer Southgate
Journal:  Biosystems       Date:  2016-06-03       Impact factor: 1.973

7.  Human Amniotic Membrane Enriched with Urinary Bladder Fibroblasts Promote the Re-Epithelization of Urothelial Injury.

Authors:  Urška Dragin Jerman; Peter Veranič; Tina Cirman; Mateja Erdani Kreft
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 8.  Recurrent Urinary Tract Infection: A Mystery in Search of Better Model Systems.

Authors:  Benjamin O Murray; Carlos Flores; Corin Williams; Deborah A Flusberg; Elizabeth E Marr; Karolina M Kwiatkowska; Joseph L Charest; Brett C Isenberg; Jennifer L Rohn
Journal:  Front Cell Infect Microbiol       Date:  2021-05-26       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.